Hepatitis C Treatment in Idaho County Jails

ConditionHepatitis C

Trial statusNot yet recruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18+

SponsorEastern Idaho Public Health

About this trial

To explore the feasibility of opt in Hepatitis C Virus (HCV) screening and initiation of HCV treatment during incarceration in county jails including;

1. incarcerated persons positive for HCV who remain in jail for duration of 12 weeks of treatment and 2. incarcerated persons positive for HCV in jails less than the duration of 12 weeks of treatment who receive remaining supply of study drug on discharge with appropriate linkage to care.

Assess quality of life measures in participants being treated for their HCV through the validated questionnaire EuroQol-5D at baseline and post-treatment.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

All participants greater than 18 years old and incarcerated in an Idaho county jail greater than 10 days.

All participants who are not sentenced to prison terms at Idaho Department of Corrections (IDOC). Participants sentenced to IDOC will receive screening and treatment per IDOC policy.

Participants diagnosed with HCV and qualify for the AASLD Simplified Treatment Algorithm for Treatment Nave Adults Without Cirrhosis.

Disqualifiers

All participants greater than 18 years old and incarcerated in an Idaho county jail greater than 10 days.

All participants who are not sentenced to prison terms at Idaho Department of Corrections (IDOC). Participants sentenced to IDOC will receive screening and treatment per IDOC policy.

Participants diagnosed with HCV and qualify for the AASLD Simplified Treatment Algorithm for Treatment Nave Adults Without Cirrhosis

Trial design

Design model

Single group

Treatments tested in this trial

sofosbuvir/velpatasvir
Drug
Patients who qualify for the study will be provided with sofosbuvir/velpatasvir for chronic hepatitis C treatment.

Treatment groups

100 Participants

are divided into 1 treatment group

Group A: Patients infected with chronic hepatitis C who are also incarcerated in an Idaho county jailOther 1 intervention

Trial outcomes

Primary outcomes

Sustained Virologic Response

Undetectable hepatitis C RNA

Time frame

12 weeks after treatment

Secondary outcomes

Quality of life improvement

Improvement in quality of life measures after treatment of hepatitis C as measured by SF-12 tool

Time frame

At study enrollment and 12 weeks after treatment

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Eastern Idaho Public Health

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: